Generic placeholder image

Current Drug Targets


ISSN (Print): 1389-4501
ISSN (Online): 1873-5592

Clonazepam for the Treatment of Panic Disorder

Author(s): Antonio E. Nardi, Sergio Machado, Leonardo Ferreira Almada, Flavia Paes, Adriana Cardoso Silva, Ricardo Jose Marques, Roman Amrein, Rafael C. Freire, Rocio Martin-Santos, Fiammeta Cosci, Jaime E. Hallak, Jose A. Crippa and Oscar Arias-Carrion

Volume 14, Issue 3, 2013

Page: [353 - 364] Pages: 12

DOI: 10.2174/1389450111314030007

Price: $65


Clonazepam was initially licensed as an anti-epileptic agent, but its use in a wide variety of psychiatric conditions, including panic disorder (PD) has now been well established. This overview evaluates the current role of clonazepam alone or in combination with antidepressants and/or behavioral therapy in the treatment of PD. We review the data establishing the use of clonazepam in the treatment of PD as well as new information, particularly confirmation of longterm efficacy and safety. We also discuss a regimen for safely tapered withdrawal of clonazepam, the characteristics of the respiratory subtype of PD, and CO2-induced panic attacks as a diagnostic measure and predictor for therapeutic success. It has been shown that panic attacks can more readily be induced by CO2 in PD patients with the respiratory subtype than those with the non-respiratory subtype. More than 25 years after the first report of efficacy in PD in 1984, clonazepam, alone or combined with selective serotonin reuptake inhibitors (SSRIs) and/or behavioral therapy, remains an important therapeutic modality for the management of PD.

Keywords: Behavioral therapy, carbon dioxide test, clinical studies, clonazepam, panic disorder, selective serotonin reuptake inhibitors, tapering, benzodiazepines, SSRIs or, anxiety symptoms

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy